{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.0","upperLimit":"31.3","value":"12.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Patients were evaluated for relapse/progression post transplant throughout the study. The cumulative incidence of relapse/progression was determined using competing risk analysis. Competing risks for relapse were non-relapse mortality and nonengraftment.","dispersionType":"95% Confidence Interval","groups":[{"description":"All patients were analyzed as a single population. Stratification by conditioning regimen was not done.","id":"OG000","title":"All Patients"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 year point estimate was provided.","title":"Incidence of Disease Relapse/Progression at 2 Years Post HSCT","type":"SECONDARY","unitOfMeasure":"Percentage of patients who relapsed"}